| Document |
Document Title |
|
WO/2017/112815A1 |
Specific Cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hE...
|
|
WO/2017/111176A1 |
Synthesis of an organic compound with chirality is an important technique in the fields of medicines, pesticides, health foods, etc. However, catalysts to be used for such synthesis are produced from expensive starting materials and, fur...
|
|
WO/2017/107993A1 |
A polyether compound shown in general formula 1, a use of the chelated form, hydrated form or pharmaceutically acceptable salt thereof in the preparation of a medicine, and a use of the medicine in the preparation of a medicine for treat...
|
|
WO/2017/103188A1 |
Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
|
|
WO/2017/101885A1 |
The present invention relates to a method for preparing a c-Met tyrosine kinase inhibitor, and specifically, relates to a method for preparing a mesylate crystalline form III of a compound represented by formula (I), namely 9-((8-fluoro-...
|
|
WO/2017/101763A1 |
Compounds of Formula (I) are shown below, and their pharmaceutically acceptable salts, hydrates, or solvates thereof. It involves pharmaceutical compositions of these compounds, their preparation, and their utilities in treating diseases...
|
|
WO/2017/104283A1 |
Provided are: a near-infrared absorbent composition with which a membrane having excellent infrared shielding properties and visible transparency can be produced; a membrane; an infrared cut filter; a solid-state imaging element; an infr...
|
|
WO/2017/101538A1 |
Provided are an epoxy resin composition and a prepreg, laminated board and printed-circuit board comprising same. The epoxy resin composition comprises the following components: (A) 38-54 parts by weight of an epoxy resin comprising a DC...
|
|
WO/2017/097234A1 |
The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositi...
|
|
WO/2017/100662A1 |
The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).
|
|
WO/2017/097671A1 |
The invention relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for producing same, to the use thereof alone or in combination for the treatment and/or preventio...
|
|
WO/2017/096163A1 |
Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
|
|
WO/2017/092083A1 |
Disclosed are a DPP-4 inhibitor compound, a polymer and a preparation method and use. The structure of said compound is X-R1-R2-Y, X and Y respectively being a group formed of a DPP-4 inhibitor or a DPP-4 inhibitor analogue containing an...
|
|
WO/2017/090719A1 |
Provided is a compound having an inhibitory effect on androgen receptors. A condensed pyrimidine compound represented by general formula (I) or a pharmacologically acceptable salt thereof (in the formula, X, Y, Z, R1, and R2 are as defin...
|
|
WO/2017/088289A1 |
The present invention relates to a novel compound being a JAK inhibitor. The compound is a compound of formula (I), its pharmaceutically acceptable salt, prodrug, metabolite, isotope derivative, and solvate, or a pharmaceutical compositi...
|
|
WO/2017/088790A1 |
The present invention belongs to the field of drug crystals, relates to crystals of thiadiazole derivative DPP-IV inhibitors, and in particular relates to A and B type crystals of the compound as shown in formula 7. The crystals of the p...
|
|
WO/2017/085484A1 |
The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the ...
|
|
WO/2017/081483A1 |
The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions contai...
|
|
WO/2017/081003A1 |
The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to...
|
|
WO/2017/077283A1 |
There are provided compounds of formula (I), wherein X, Ak, s, L, Q, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) a...
|
|
WO/2017/076990A1 |
The present invention is directed to crystalline addition salts of (I) N-[4-(4-{[(1S)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo
[2,1- f][1,2,4]triazin-2-yl)ethyl]amino}-7H-pyrrolo[2,3-d]pyrimidi
n-5-yl) -1 H-indol-6-yl]sulfamide with...
|
|
WO/2017/079519A1 |
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, car...
|
|
WO/2017/079558A1 |
The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified em...
|
|
WO/2017/077968A1 |
A condensed heterocyclic compound represented by formula (II), in which Q represents a group represented by formula Q-1 or a group represented by formula Q-2, has an excellent control effect on arthropod pests (wherein, Z represents a ni...
|
|
WO/2017/072039A1 |
The invention relates to novel compounds of formulae (I) or (Γ) (formula I, II) wherein R1, R2, R3, Aa, Ab, Ac, Ad, Ae, Q and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for con...
|
|
WO/2017/071516A1 |
The invention provides a compound having a structural formula I, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a compound form thereof, or a compound comprising the structural formula I, or a pharmaceutical acceptable sa...
|
|
WO/2017/067422A1 |
The present invention relates to an organic compound as shown in formula (I), said compound being an organic phosphorescent light-emitting material. Carbazoline is bonded to an aromatic ring, the organic compound has good solubility in a...
|
|
WO/2017/069279A1 |
Provided is a compound that has an effect of inhibiting RIP1 kinase and is useful as a prophylactic or therapeutic agent for Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiples sclerosis, chronic nephropathy, a...
|
|
WO/2017/069270A1 |
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...
|
|
WO/2017/069661A1 |
The invention relates to novel pyrimidyl-di(diazaspiro-alkane) derivatives of formula (I) or a pharmaceutically acceptable acid additive salt thereof. The compounds exhibit a wide spectrum of antiviral activity against herpes virus, huma...
|
|
WO/2017/069275A1 |
The present invention provides a novel compound having excellent inhibitory action against KAT II, a production method therefor, a use therefor, and a pharmaceutical composition, or the like, that includes the compound. Provided is the c...
|
|
WO/2017/066633A1 |
We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
|
|
WO/2017/060874A1 |
The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment...
|
|
WO/2017/061497A1 |
Since damage due to harmful insects and the like remains significant in the production of agricultural or horticultural crops, the present invention provides a condensed heterocyclic compound or salts thereof, said compound being a new i...
|
|
WO/2017/060873A1 |
The present invention provides for compounds of formula (I), wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of dis...
|
|
WO/2017/060879A1 |
A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
|
|
WO/2017/059289A1 |
The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conj...
|
|
WO/2017/059191A1 |
Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and imm...
|
|
WO/2017/056055A1 |
Benzimidazolo[1,2-a]benzimidazole carrying triazine groups, an organic electronic device, comprising said benzimidazolo[1,2-a]benzimidazole carrying triazine groups, an electron transport layer, an electron injection layer, or an emittin...
|
|
WO/2017/057747A1 |
The objective of the present invention is to provide: a compound and a composition for forming an organic semiconductor film, each of which enables the formation of an organic semiconductor film having excellent heat resistance; an organ...
|
|
WO/2017/050732A1 |
The invention provides novel compounds having the general formula (I), (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2017/049711A1 |
Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relievin...
|
|
WO/2017/045510A1 |
Provided are compounds shown in general formulae (I)-(IV) capable of being used as β-lactamase inhibitors, pharmaceutically acceptable salts thereof, esters thereof, and stereoisomers thereof, where R1, R2, M, and a ring A are as define...
|
|
WO/2017/046675A1 |
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined ...
|
|
WO/2017/046606A1 |
This invention relates to antibacterial and antimycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in tre...
|
|
WO/2017/043175A1 |
Provided is a near-infrared absorbing curable composition which is capable of forming a cured film that has excellent infrared light shielding properties and visible light transparency, while exhibiting excellent heat resistance and ligh...
|
|
WO/2017/042182A1 |
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substi...
|
|
WO/2017/042114A1 |
The present invention relates to compounds of formula (I); hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted b...
|
|
WO/2017/043550A1 |
The purpose of the present invention is to provide a novel RET inhibitor and a prophylactic or therapeutic agent for diseases that can be prevented or treated with the assistance of a RET inhibition activity (e.g., malignant tumors), eac...
|
|
WO/2017/040448A1 |
The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated a...
|
